发布时间:
来源: 粤港澳头条
File photo shows a staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing. (Xinhua File/Zhang Yuwei)
A phase 2 trial of a COVID-19 vaccine candidate in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.